8/17/2019 Monitoring Efek Samping Obat 12
1/36
Monitoring Efek Samping
Obat
8/17/2019 Monitoring Efek Samping Obat 12
2/36
8/17/2019 Monitoring Efek Samping Obat 12
3/36
Managing ADRsManaging ADRs
8/17/2019 Monitoring Efek Samping Obat 12
4/36
Dr. Donald Brodie, 1965 :
“ The ultimate goal of the
Services of Pharmacmust !e
the S"#$ %S$ of D&%'S
! the Pu!lic “
8/17/2019 Monitoring Efek Samping Obat 12
5/36
Efek Samping Obat (ADR)
• ADR : an eect which is noxious anunintene! an which occurs atoses use in man for proph"#axis!iagnosis or therap" ($%O)
• Adverse drug event : an in&ur"resu#ting from meica# inter'entionre#ate to a rug (ates et a#!
**+b)• Medication error : an error in
orering! transcribing! ispensing!aministering a meication
8/17/2019 Monitoring Efek Samping Obat 12
6/36
De,nitions
• Quality of life (Schron - Schumaker)
a mu#tiimentiona# concept referring to a person.s tota#we##/being inc#uing his or her ps"cho#ogica#! socia# anph"sica# hea#th status
the 'a#ue assigne to uration of #ife as moi,e b" theimpairments! functiona# status! perception an socia#opportunities that are in0uence b" iseases! in&ur"!treatment or po#ic" (1atrick - Erickson)
HEALTH OUTCOME =
HEALTH-RELATED QUALT! O" L"E
8/17/2019 Monitoring Efek Samping Obat 12
7/36
8/17/2019 Monitoring Efek Samping Obat 12
8/36
2334 #atient-$%eci&c 5#inica#1harmac" Ser'ices in %ospita#s
Pharmacokinetic ConsultationPharmacokinetic Consultation 87%87%
ADR Management ADR Management 81%81%
Drug Protocol ManagementDrug Protocol Management 77%77%
Drug Therapy MonitoringDrug Therapy Monitoring 6%6%
Me!ical Roun!s ParticipationMe!ical Roun!s Participation "1%"1%
Drug Therapy CounselingDrug Therapy Counseling #6%#6%
TP$ Team ParticipationTP$ Team Participation #"%#"%
CPR Team ParticipationCPR Team Participation 7%7%
A!mission Drug istories A!mission Drug istories 7&"%7&"%
'on! CA( Raehl( C)& Pharmacotherapy *++8,*8-1./101&
8/17/2019 Monitoring Efek Samping Obat 12
9/36
6 %ospita# 5#inica# 1harmac"Ser'ices Sa'e 7i'es
• Drug use e'a#uation
• 8n/ser'ice eucation
• A'erse rug reaction management• 1articipation on 51R team
• Drug protoco# management
• 1articipation on meica# rouns• Amission rug histories
'on! CA( Raehl C)& Clinical Pharmacy er2ices( Pharmacy ta33ing(
an! ospital Mortality Rates& Pharmacotherapy *++7,*7-#./#810#4&
8/17/2019 Monitoring Efek Samping Obat 12
10/36
5#inica# 1harmac" Ser'ices8mpro'e 5are
• Decrease 5 A'erse rug e'ents
5 A'erse meication reactions
5 Meication errors
• 8mpro'e 5 Meication aherence
5 Drug know#ege
5 Appropriate meication use
• Shortene #ength of hospita# sta"
9abo#i 1 et a#; 5#inica# 1harmacists an 8npatient Meica# 5are:
A S"stematic Re'iew;
Arch 8ntern Me; 2334
8/17/2019 Monitoring Efek Samping Obat 12
11/36
ESO
• SE>8A1 E?E9 OA> @ D1>MEMA%A@A9AB C MER89AB S81EMA9A8! AB8B @ D89ABDB
MA1B A@8 @ AR 7A%8R• ESO 8B8! @8C E?E9 SAM18B 1D DOS8S
BORMA7 B>; >AB 1RO?87A9S8S!D8ABOS8S MA1B 1EBOA>AB;
• 1EBBAAB OA> @ MEB8B9A>DOS8S MA1B ?RE9; B@A A1> AD89S8
A D8MAS99AB D7M ESO
8/17/2019 Monitoring Efek Samping Obat 12
12/36
AB9A 9EAD8AB
• %AM18R SEMA OA> @ E?E9>8?D1> MEB8M79AB ESO
8/17/2019 Monitoring Efek Samping Obat 12
13/36
1EB@EA ESO
REA9S8 A98A> 9E7A8ABAB A$AABA7ER8 :>D 9RB ME9AB8SME 8MBO7O8!
S8?A>: >D9A ADA %; DB S8?A>?ARMA9O7O8! >8M7 1D DOS8S 9E587
ESO 9RB 9E7A8BAB EBE>89
ESO 9RB 9E7A8BAB @ D8DA1A>! E:ADAB@AABAB %A>8 @
MEBAB DE>O9S8?89AS8 OA>!ABAB 8BA7 @ MEBABE78M8BAS8 OA> M8SA7 EB>AM8S8B8SA MEB@EA9AB >78;
8/17/2019 Monitoring Efek Samping Obat 12
14/36
1EB@EA ESO
• 9E7A8BAB A98A> EB>9 SER>A5ARA 1EMER8AB OA> 5 R @ >D A98A> 1ERA%AB
8OAFA8A7878>AS! A>A 5ARA1EMER8AB @ 9RAB >E1A> : M8SA7E?E9A D8>8?! A%AB 1E7AR>!1EBA$E> @ D8>AMA%9AB SAA>
1EMA>AB OA>• 8B>ERA9S8 OA>
8/17/2019 Monitoring Efek Samping Obat 12
15/36
?A9>OR 1RED8S1OS8S8 >8M7B@A ESO
• SAA> >8M7B@A REA9S8
5 ESO DA1A> >8M7 1D A$A71EBOA>AB (A@O9 ABA?87A9S8S 9RB
1EMER8AB 1EB8S878B) 5 SE>E7A% 1EBOA>AB ER7ABSB
7AMA (RE>8BO1A>8 9RB 1EBOA>ABDB 97ORO98B)
5 >8M7 7AMA SE>E7A% OA> D8%EB>89AB( 9ARS8BOMA A98A> 1EMER8ABD8E>87S>87ES>ERO7)
8/17/2019 Monitoring Efek Samping Obat 12
16/36
MR8BS8DEB ESO MEB8B9A> 1D 1EBDER8>A
MDA - S8A 7AB> 9OBD8S8 1A>O?8S8O7O8S
EERA1A 1EB@A98> @ MEB@ER>A81EBDER8>A 8SA MEROA%
?ARMA9O98BE>89 OA>! ( %A>8 G 1RMER8ABE>A 7O9ER 1D ORAB ASMA)
M7A% OA> @? D8ER89AB1EBOA>AB @ >ER7A7 7AMA 8SA
MEB5E>S9AB >8M7B@A ESO
EB8S 9E7AM8B%AS87 1EBE78>8AB : $AB8>A 7E8% MDA%
MEBA7AM8 ES8 D8D 7A98H
8/17/2019 Monitoring Efek Samping Obat 12
17/36
• R8$A@A> A7ER8 SEE7MB@A 5 1EBDER8>A DB R8$A@A> A7ER8 S7MB@A
7E8% 1E9A MEBDA1A> R; ESO EREB>9A7ER8 DAR 1EBDER8>A BORMA7
• M7>817E DRS >%ERA18 5 MA98B AB@A9 M7A% OA> @ D8ER89AB
MA98B I 9EMB98BAB 9EBA ESO
• ?A9>OR RAS8A7 A>A EBE>89 5 D8DA ADA 1EBAR% RAS8A7 C EBE>89
B>9 >8M7B@A ESO >ER>EB>
8/17/2019 Monitoring Efek Samping Obat 12
18/36
Masa#ah / DAM1A9
• Assessment SEARA% E?E9 SAM18B! MR!EBE>89
• 1AS8EB >D9 MEBDA1A> 8B?O 591 >EB>ABE?E9 SAM18B
• 8DEB>8>ASC1EBABDA 1ERBA% MEBA7AM8E?E9 SAM18B
• E?E9 SAM18B A98A> >8DA9 MEBDA1A> OA> @AB >E1A>
• MOR8D8>AS >RB• 8A@A
8/17/2019 Monitoring Efek Samping Obat 12
19/36
Macam ADR
• T!#E A' intrinsic 5 (isa di%redi)si' di*ung)in)an
%encega+an 5 Ada +u,ungan dengan dosis
5 $ering teradi ./01-2013' td) fatal• T!#E (' idiosyncratic 5 $u)ar di%redi)si 5 Td) tergantung dosis 5 $ering)ali fatal
5 Me*erlu)an %o%ulasi ,esar untu)*engeta+ui )eadian 5 U*u*nya individual se)ali' td) ta*%a)
dl* ,inatang
• AD4E' 5idra5al events
8/17/2019 Monitoring Efek Samping Obat 12
20/36
Efek Samping Obat!9enapa per#u iMonitor J
• Merupakan ampak negatif aripengobatan
• 9ontra prouktif terhaappengobatan rasiona#
• >ingkat ke&aian re#atif keci#
• Dipengaruhi faktor ini'iua# pasien• 9eterbatasan preiksi a#am proses
pengembangan obat baru
8/17/2019 Monitoring Efek Samping Obat 12
21/36
>he phases of rug e'e#opment in the S (Smith! *6K< 9ait#in et a#;!*K6< an @oung et a#;! *KK)
1RE578B85A7 >ES>8B Anima#
578B85A7 >ES>8B1%ASE 8 : Borma# 'o#unteers1%ASE 88 : se#ecte patients1%ASE 888 : #arge samp#e of
se#ecte patients
BDA REF8E$
1OS>MAR9E>8B SRFE877AB5E1%ASE 8F :
1atients gi'en rug for therap"
8n 'itro
Safet"!bio#ogica# eects!
Metabo#ism!9inetics!
Drug interactions
ADR!patterns of rug uti#iLation!
8/17/2019 Monitoring Efek Samping Obat 12
22/36
8/17/2019 Monitoring Efek Samping Obat 12
23/36
8/17/2019 Monitoring Efek Samping Obat 12
24/36
?A9>OR @ ER1EBAR% >8M7B@AE?E9 SAM18B
DRU6 DO$E ROUTE DURATO7
#RE#ARATO7 #ATE7T
#HARMACO87ETC 9ARA(LE$ A6E 6E7ETC$
ALLER6! 7"ORMATO7
A($E7T OR 7 ADEQUATE
8/17/2019 Monitoring Efek Samping Obat 12
25/36
1ERAB ?ARMAS8S th E?E9 SAM18B J
• MEMA%AM8 ADR DB 8B?O >ER98B8
• MEBEBA78 ADR
• 8B>ERFEBS8 5 S>O1C>E>A1 OA>
5 9OBSE78B
51EBABDA
• E?E9>8? ME7A1OR9AB 9EAD8AB
• S8S>EM MESO
8/17/2019 Monitoring Efek Samping Obat 12
26/36
?7O$5%AR> O? ASSESSMEB>ABD MABAEMEB> O? AB ADR
DETECTO7O" #O$$(LE ADR
#U(L$HED LTERATURE RE9E4 #ATE7T-$#EC"C DATA
CO7T7UE DRU6
DECHALLE76E
RE5%A77EBE
COM#ARE #: REACTO7 TODE$CR#TO7 7 THE LTERATURE
E9ALUATE $E9ERT!
E9ALUATE #ATE7T
8/17/2019 Monitoring Efek Samping Obat 12
27/36
(%$ST)*+ $S +*
D*
+*T
-+*
9.1.1 "re there /revious conclusive re/orts on
this reaction0
1 2 2
9.1.3 Did the adverse event a//ear after the
sus/ected drug 4as administered0
3 1 2
9.1. Did the adverse reaction im/rove 4hen the
drug 4as discontinued or s/ecific
antagonist 4as administered0
1 2 2
29.1.7 Did the adverse reaction rea//ear 4hen the
drug 4as readministered0
3 1 2
9.1.5 "re there alternative causes 8other than the
drug that could on their o4n have caused
the reaction0
1 3 2
9.1.6 Did the reaction rea//ear 4hen a /lace!o4as given0
1 1 2
9.1. as the drug detected in the !lood 8or
other fluids in concentration ;no4n to !e
to
8/17/2019 Monitoring Efek Samping Obat 12
28/36
1enekatan 1E7A1ORABMESO
• 9oluntery' 5 ,ai) untu) %ene*uan E$O ,aru
5 Le,i+ *enani)an dari %ende)atan lain
• Co+ort study 5 8erasa*a ti* .do)ter' far*asis' %era5at3
5 "re)uensi Eso sela*a ra5at
• Mandatory 5 8e+arusan ,edasar as%e) legal
5 Data tinggi' validitas diragu)an• Record lin)age
5 Catatan *edi)' ,ervariasi E$O terli%ut
5 Data terlalu ,ervariasi
8/17/2019 Monitoring Efek Samping Obat 12
29/36
1e#aporan MESO RA$A> A7AB RSethesa
KELOMPOK FARMAKOLOGI
N = 29 kasus (Juni - Des 2004)
52
00
!"
0#
!
Antiin3eksitot kelet en!i
al& $apas
P
ar!io2askuler
al& Cerna
ormon
MANIFE$%A$I E$O
N=29 kasus (Juni-Des 2004)
!9
2"
!
&0
&0
!# 8ulit
1aluran Cerna
1aluran $apas
1istem sara3
8ar!io2askuler
Mata
9:tremitas
8/17/2019 Monitoring Efek Samping Obat 12
30/36
;hat is the role o3 pharmacist in PTC
N Managing adverse drug reactions .ADRs3
/ the pharmacist must aress the issue of a'erse rug reactions on a regu#ar basis since hospita#
amissions resu#ting from a'erse rug reactions accounts for /6P of patients; >hese o not
inc#ue errors of aministration! which wou# on#" increase the tota# incience of morbiit" an morta#it";
8/17/2019 Monitoring Efek Samping Obat 12
31/36
Managing ADRs
#+ar*acists s+ould facilitate ;
/ ana#"sis of each reporte ADR/ ientif" the rug an patient at high risk for being in'o#'e in ADRs
/ e'e#op po#icies an proceures for ADR monitoring an reporting program/ use ADR program for eucationa# purposes/ e'e#op! maintain an e'a#uate ADR recors within the organiLation/ report serious ADR to Ministr"! ?DA or manufacturer
8/17/2019 Monitoring Efek Samping Obat 12
32/36
Manfaat pe#aporan
• 1erubahan 9ebi&akan Basiona7
(9asus penarikan obat ppa/?DA)
• 1erubahan 9ebi&akan 7oka# ( rumahsakit)
• 1raktisi waspaa a#am farmakoterapi
• Mencegah timbu#n"a efek samping
beru#ang
• 8nformasi muncu#n"a efek samping"ang baru an membaha"akan
8/17/2019 Monitoring Efek Samping Obat 12
33/36
Manfaat k#inik
• 8nformasi penting a#ampengambi#an keputusan : Rasio*anfaat ter+ada% resi)o
• 8nformasi terkini untuk penekatankonisi pasien terhaap respon obat
• Mencegah ke&aian kemba#i paa
kasus serupa• Menurunkan morbiitas an
morta#itas
8/17/2019 Monitoring Efek Samping Obat 12
34/36
9er&asama
9eamanan mas"arakat a#am aspekobat aa#ah tanggung profesikesehatan
• 1er#u sistem ker&asama enganmas"arakat #uas an 18%A9 >ER9A8>(1emerintah)
• >erbuka untuk komunikasi nasiona#maupun internasiona#
8/17/2019 Monitoring Efek Samping Obat 12
35/36
A#amat pe#aporan
2?
R$/@/1
8/17/2019 Monitoring Efek Samping Obat 12
36/36
Safe use ofprescription
meication• A'oi agents / either foo!a#coho#! other rugs / thatma" ecrease eecti'eness orincrease sie eects;
• RecogniLe sie eects anknow what to o if the" occur;
• nerstan inications anexpectations for theprescribe agents
• 1erioica##" re'iewmeications
• et prescription re,##e ina'ance